Trends in Streptococcus pneumoniae Antimicrobial Resistance in US Children: A Multicenter Evaluation
Open Forum Infectious Diseases · 03.03.2023 · 10 (3)
DOI: 10.1093/ofid/ofad098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 07.03.2023. Verfasst von Salini Mohanty und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Observational and Real World Evidence (CORE), Merck & Co, Inc, Rahway, New Jersey, USA. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, (MSD), Merck & Co, Inc.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Antimicrobial resistance (AMR) poses a significant challenge for treating pneumococcal disease. This study assessed AMR trends in Streptococcus pneumoniae from US children.
Methods
We evaluated antibiotic resistance, defined as facility antimicrobial susceptibility reports of intermediate/resistant, in 30-day nonduplicate S pneumoniae isolates from children (<18 years of age) with invasive (blood or cerebrospinal fluid/neurological) or noninvasive (respiratory or ear/nose/throat) isolates at 219 US hospital inpatient/outpatient settings in the BD Insights Research Database (January 2011–February 2020). We used descriptive statistics to characterize the percentage of antimicrobial-resistant isolates and generalized estimating equations to assess variations in resistance over time.
Results
Of 7605 S pneumoniae isolates analyzed, 6641 (87.3%) were from noninvasive sources. Resistance rates were higher in noninvasive versus invasive isolates. Isolates showed high observed rates of resistance to ≥1 drug class (56.8%), ≥2 drug classes (30.7%), macrolides (39.9%), and penicillin (39.6%) and significant annual increases in resistance to ≥1 drug class (+0.9%), ≥2 drug classes (+1.8%), and macrolides (+5.0%).
Conclusions
Among US children over the last decade, S pneumoniae isolates showed persistently high rates of resistance to antibiotics and significant increases in ≥1 drug class, ≥2 drug classes, and macrolide resistance rates. Efforts to address AMR in S pneumoniae may require vaccines targeting resistant serotypes and antimicrobial stewardship efforts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Observational and Real World Evidence (CORE), Merck & Co, Inc, Rahway, New Jersey, USA.
- Becton, Dickinson & Company, Franklin Lakes, New Jersey, USA.
ORCID-Profile: Vikas Gupta
Förderung
- Merck Sharp & Dohme LLC
- (MSD)
- Merck & Co, Inc
- Becton, Dickinson & Company
Zitieren
APA
Mohanty, S., Feemster, K., Yu, K. C., Watts, J. A., & Gupta, V. (2023). Trends in Streptococcus pneumoniae Antimicrobial Resistance in US Children: A Multicenter Evaluation. Open Forum Infectious Diseases, 10(3). https://doi.org/10.1093/ofid/ofad098
Vancouver
Mohanty S, Feemster K, Yu KC, Watts JA, Gupta V. Trends in Streptococcus pneumoniae Antimicrobial Resistance in US Children: A Multicenter Evaluation. Open Forum Infectious Diseases. 2023;10(3). doi:10.1093/ofid/ofad098
BibTeX
@article{Mohanty2023,
author = {Mohanty, Salini and Feemster, Kristen and Yu, Kalvin C and Watts, Janet A and Gupta, Vikas},
title = {Trends in Streptococcus pneumoniae Antimicrobial Resistance in US Children: A Multicenter Evaluation},
journal = {Open Forum Infectious Diseases},
year = {2023},
volume = {10},
number = {3},
doi = {10.1093/ofid/ofad098}
}
EUVIMED